Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Rix Brooks

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 24, 2020
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosisJinsy A Andrews, Carlayne E Jackson, Terry D Heiman-Patterson, et al.
The Lancet. Neurology|September 21, 2016
Amyotrophic lateral sclerosis: moving towards a new classification systemAmmar Al-Chalabi, Orla Hardiman, Matthew C Kiernan, et al.
Annals of Neurology|September 15, 2010
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affectErik P Pioro, Benjamin Rix Brooks, Jeffrey Cummings, et al.
Respiratory Care|March 5, 2020
The Oral Secretion Scale and Prognostic Factors for Survival in Subjects With Amyotrophic Lateral SclerosisPamela A Cazzolli, Benjamin Rix Brooks, Yuki Nakayama, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 4, 2022
A revision to the United States national ALS registry's algorithm to improve Case-AscertainmentPaul Mehta, Jaime Raymond, Moon Han, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|March 3, 2010
Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosisMohammed Sanjak, Francois Salachas, Elizabeth Frija-Orvoen, et al.
Neurodegenerative Disease Management|November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study designBjörn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Neurology|July 31, 2023
Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in NeurologyKathryn A Kvam, Michael Benatar, Alisa Brownlee, et al.
Neurology|November 26, 2013
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of NeurologyRobert G Miller, Benjamin Rix Brooks, Rebecca J Swain-Eng, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 24, 2020
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosisJinsy A Andrews, Carlayne E Jackson, Terry D Heiman-Patterson, et al.
The Lancet. Neurology|September 21, 2016
Amyotrophic lateral sclerosis: moving towards a new classification systemAmmar Al-Chalabi, Orla Hardiman, Matthew C Kiernan, et al.
Annals of Neurology|September 15, 2010
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affectErik P Pioro, Benjamin Rix Brooks, Jeffrey Cummings, et al.
Respiratory Care|March 5, 2020
The Oral Secretion Scale and Prognostic Factors for Survival in Subjects With Amyotrophic Lateral SclerosisPamela A Cazzolli, Benjamin Rix Brooks, Yuki Nakayama, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 4, 2022
A revision to the United States national ALS registry's algorithm to improve Case-AscertainmentPaul Mehta, Jaime Raymond, Moon Han, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|March 3, 2010
Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosisMohammed Sanjak, Francois Salachas, Elizabeth Frija-Orvoen, et al.
Neurodegenerative Disease Management|November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study designBjörn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Neurology|July 31, 2023
Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in NeurologyKathryn A Kvam, Michael Benatar, Alisa Brownlee, et al.
Neurology|November 26, 2013
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of NeurologyRobert G Miller, Benjamin Rix Brooks, Rebecca J Swain-Eng, et al.
Pageof 5